Skip to content

Internal Iliac Artery Occlusion in Placenta Accreta

Perioperative Prophylactic Bilateral Internal Iliac Artery Occlusion in Placenta Accreta: a Randomized Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04423263
Enrollment
24
Registered
2020-06-09
Start date
2020-07-01
Completion date
2023-12-31
Last updated
2020-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Placenta Accreta

Keywords

balloon occlusion, iliac artery, interventional radiology, postpartum hemorrhage, blood transfusion

Brief summary

This is a randomized study to assess the efficacy of prophylactic bilateral internal iliac artery occlusion performed prior to planned surgical management for placenta accreta spectrum (PAS). The intervention group would receive balloon occlusion, ureteric stenting and caesaeran hysterectomy while the control group would undergo the same procedure, excluding balloon occlusion. The primary outcome is to demonstrate a three pint or greater reduction in pack cell transfusion requirement.

Detailed description

Interventional radiology, including internal iliac artery occlusion, has been used as an adjunct in the management of placenta accreta spectrum (PAS). Retrospective studies have shown benefit in terms of reduction of blood loss. However, studies reported in literature vary widely in terms of the exact surgical procedure undertaken, in conjunction with the radiological intervention. The radiological intervention itself lacks standardization, occurring at different anatomical levels, ranging from infrarenal aortic occlusion to internal iliac or uterine artery. Furthermore, there have been reported cases of arterial thrombosis associated with arterial occlusion. We sought to clarify the effectiveness of a standardized approach , where perioperative bilateral internal iliac artery occlusion is performed followed by bilateral ureteric stenting and caesarean hysterectomy. The control group would undergo the exact procedure, excluding internal iliac artery occlusion. Patients would be randomized but neither the patient nor surgeon could be blinded. The primary outcome would be to demonstrate a three pint or greater reduction in packed cell transfusion. Secondary outcomes include a difference in estimated blood loss, additional blood product transfusion, unplanned additional surgical procedure, serious complications arising from internal iliac artery occlusion, total procedural time and early neonatal outcome.

Interventions

Bilateral internal iliac artery balloon placement under fluoroscopic guidance preoperatively which will be occluded intraoperatively based on existing local protocol

PROCEDUREControl

Surgical approach similar to intervention arm, except bilateral internal iliac artery occlusion

Sponsors

Voon Hian Yan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* All pregnant women with prenatally diagnosed placenta accreta spectrum

Exclusion criteria

* Women who declined to participate * Women with bleeding diathesis or severe thrombocytopenia \<100k x 1,000,000/L * Surgery performed prior to 28 weeks of gestation

Design outcomes

Primary

MeasureTime frameDescription
Pack cell transfusionFirst 7 days post-operativelyTo detect a three pint reduction in pack cell transfusion

Secondary

MeasureTime frameDescription
Other blood componentsFirst 7 days post-operativelyPlatelets, fresh fozen plasma, cryoprecipitate
Unplanned perioperative surgical proceduresFirst 7 days post-operativelyInternal iliac artery ligation, abdominal packing, relaparotomy
Complication from internal iliac occlusionFirst 14 days post-operativelydeath, arterial thrombosis, aneurysm, hematoma requiring evacuation

Other

MeasureTime frameDescription
Operative timePerioperativeTotal time taken for procedure
Neonatal complicationFirst 24 hoursApgar, cord pH, resuscitation, neonatal intensive care admission

Contacts

Primary ContactHian Yan Voon, MRCOG
vhaxyn@gmail.com+6082 276666

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026